Navigation Links
Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy
Date:9/19/2011

e of breast cancer recurrence at 17 months of median follow-up in patients treated with the AE37 peptide vaccine in the ongoing trial. The authors concluded that the AE37 vaccine is safe and well-tolerated with the ability to generate sustained, robust in vitro and in vivo immune response in vaccinated breast and prostate cancer patients.

"We are pleased to see that as the data from clinical trials accumulate, AE37 continues to show that it is not only on track to achieve a positive endpoint in the treatment of breast cancer, but also shows clear advantages over other peptide and cancer vaccine strategies," said Eric von Hofe, Ph.D., President of Antigen Express.  "The clinical path forward for AE37 is straightforward, with the Phase III trial designed and ready to be implemented."

Per trial design in the ongoing Phase II study, patients are being followed for clinical recurrences; data regarding the efficacy of the AE37 vaccine will be reported after a median follow-up of 24 months. Antigen Express anticipates being able to hold an end of Phase II meeting with the FDA in the second half of 2012, followed by initiation of a pivotal Phase III trial. The company is currently seeking a partner for Phase III development and commercialization.

About AE37

Antigen Express' novel Ii-Key Hybrid Preventive HER-2/neu Peptide Vaccine (AE37) is an "off-the-shelf" cancer immunotherapy product candidate that is easier and less costly to produce than comparable cell-based approaches.  AE37 is derived from a fragment of the HER2 oncoprotein, which is expressed in a variety of tumors including 75-80% of breast cancers as well as a high percentage of prostate, ovarian and other cancers. AE37 is positioned initially as an adjuvant therapy for at least 50% of breast cancer patients; i.e., those with low-to-intermediate levels of HER-2 expression who are not eligible for treatment with trastuzumab (Herceptin®).  Only 25% of breast ca
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Generex Provides Update on Spinout of Antigen Express
2. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
3. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
4. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
5. BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
6. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
7. Antigen Discovery, Inc. Awarded Grant for Chlamydia Vaccine Development
8. ImmunoVaccine Technologies Licenses Immunotopes Breast, Ovarian and Prostate Cancer Antigens
9. Medicago succesfully expresses VLP antigen for A H1N1 strain
10. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
11. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 24, 2014  Last week, Representatives Gus ... (D-NC) took a bold bipartisan step on behalf ... OPEN Act. Original co-sponsors of the legislation include ... will incentivize drug makers and innovators to "repurpose" ... pediatric cancers, which opens the door to the ...
(Date:11/24/2014)... 2014 Continental Clinical Solutions, LLC ... clinical trials at its mid-Atlantic late-phase research facility, ... created with the idea of closing patient disparities ... in medical advances," said Continental's CEO, Saleh ... the immortal cell line of Henrietta Lacks, dubious ...
(Date:11/23/2014)... St. Francis, WI (PRWEB) November 23, 2014 ... based manufacturer and supplier of fine chemical ingredients ... industries announced the launch of its new website, ... a description of Apiscent Labs, clean design, easy ... qualities that make Apiscent Labs stand out. ...
(Date:11/22/2014)... 2014 RURO, Inc., a leading ... released Limfinity® version 5.1.4. , RURO’s deployment teams ... than ever in RURO’s 8 year history. Many ... enhancement. Limfinity® version 5.1.4 is the perfect example ... bug fixes! , Limfinity® 5.1.4 release highlights – ...
Breaking Biology Technology:OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3RURO Announces Limfinity® version 5.1.4 2
... -- PARIS, September 20, 2010 ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... a central alternative to petroleum-based energy production. However, current ... yield and is more expensive to mass-produce. In addition, ... on the environment is incomplete, experts say. To ... of solar power, a research team from Rochester Institute ...
... contribution to the accelerated development of new, safe ... in the US and around the world, will ... between Arizona State University and Quintiles ( www.quintiles.com ... is a leader in managing clinical research. ...
Cached Biology Technology:Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 2Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 3Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 4Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 5Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 6Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 7Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 8Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 9Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 10Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 11Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 12Research team assesses environmental impact of organic solar cells 2Drug Development in Arizona Gets Boost Following ASU-Quintiles Agreement 2
(Date:11/21/2014)... VIEW, Calif. , Nov. 20, 2014 ... higher driver efficiency are piloting the North American and ... number of accidents growing, gesture recognition systems that are ... make a mark in the industry. ... the Automotive Gesture Recognition Market in Europe ...
(Date:11/18/2014)... , Nov. 17, 2014   ... and EMC collaborate to develop The Partners Data ... , The Partners Data Lake will allow researcher ... improve diagnostics, treatment and the lives of patients ... research and clinical activities across the Partners system, ...
(Date:11/12/2014)... 2014 Crossmatch™, a leading provider of biometric ... fingerprint readers have been deployed throughout Montparnasse Pasteleria, ... Mexico . The bakery chain implemented the Crossmatch ... caused by employees clocking in for each other. ... Montparnasse relied on paper timecards and a mechanical time ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... Opening up a new door in synthetic biology, a ... produces a continuous supply of tiny lipid spheres that ... membrane. "Cells are essentially small, complex bioreactors enclosed by ... California, Irvine. "Effectively producing vesicles with lipid membranes that ...
... TEMPE, Ariz. Humans are having an effect on Earth,s ... the warming of the planet we are causing. Now you ... are leaving behind. The only question is how large of ... in the current issue of Science (Dec. 16, ...
... one step closer, thanks to a new twist on an ... Illinois researchers, led by professors Jianjun Cheng and Fei Wang, ... segments to cells. The team published its work in the ... these are new materials that could potentially be used for ...
Cached Biology News:Researchers assess effects of a world awash in nitrogen 2Let's do the twist: Spiral proteins are efficient gene delivery agents 2Let's do the twist: Spiral proteins are efficient gene delivery agents 3
... DNA Polymerase is ideal for high-fidelity ... applications such as cloning and mutagenesis. ... a proprietary enzyme preparation containing recombinant ... proofreading (3'Cut Site5' exonuclease) activity. ...
... BV-10 offers precision beveling of ... 50m. The unique abrasive plate ... for greater control of the ... accomplished very rapidly and produces ...
... 2 mM sodium phosphate buffer, pH 6.5. ... is a major lysosomal aspartyl protease in ... proenzyme. Overexpression of cathepsin D in human ... of relapse and metastasis. Cathepsin D degrades ...
Rat Hepatocytes (RH) (>3,000,000 cells)...
Biology Products: